newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics to Participate in Raymond James LILRB/ILT Symposium: Deep Dive into "Myeloid Checkpoint" Therapeutics in Cancer

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce manag